Navigation Links
IU research team discovers TB disease mechanism and molecule to block it
Date:2/15/2010

INDIANAPOLIS Indiana University School of Medicine researchers have identified a mechanism used by the tuberculosis bacterium to evade the body's immune system and have identified a compound that blocks the bacterium's ability to survive in the host, which could lead to new drugs to treat tuberculosis.

Zhong-Yin Zhang, Ph.D., Robert A. Harris Professor and chairman of the Department of Biochemistry and Molecular Biology, and his colleagues revealed the biochemical processes that TB bacteria employ to subvert macrophages key infection-fighting cells in this week's online early edition of the Proceedings of the National Academy of Sciences. They also described a compound they have synthesized I-A09 that blocked the TB bacterium's activity in laboratory tests.

About one-third of the world's population is infected with TB, a contagious disease that causes nearly 2 million deaths annually, according to the Centers for Disease Control and Prevention. Although medicines to treat TB are available, they must be taken for at least six months to fully eliminate all TB bacteria from the body. People who do not follow the lengthy treatment regimen can become sick and infectious with a more virulent form of the disease that is resistant to standard medicines.

The compound synthesized by the IU group is a proof of concept that a small molecule drug targeted against an essential virulent factor of the TB bacterium can be an effective strategy, Zhang said. If it can be developed into an approved drug, the result could significantly shorten treatment times for TB, he said.

The focus of the research was TB actions inside macrophages, which are infection fighting cells in the body's immune system. Macrophage cells' tools include the production of special proteins called cytokines to attack foreign invaders. Infected macrophages can also initiate a self-destruction mechanism called apoptosis, which signals other immune system cells to mount a defense against the infection.

TB bacteria are able to disable the macrophage defenses by secreting virulent factors into the host. The IU team found that the actions of a particular virulent factor a protein phosphatase enzyme called mPTPB blocked both the production of the infection-fighting cytokines, and the macrophage's self-destruct system.

Using combinatorial chemical synthesis and high-throughput screening, the researchers developed the I-A09 compound, which successfully blocked the action of mPTPB. Tests involving live TB bacteria were conducted at the Institute of Tuberculosis Research, University of Illinois at Chicago.

Currently, compound I-A09 is being evaluated in a TB animal model at the Johns Hopkins University School of Public Health. More potent forms of the I-A09 compound are being pursued by the IU team for possible future clinical testing, Dr. Zhang said.


'/>"/>

Contact: Eric Schoch
eschoch@iupui.edu
317-274-7722
Indiana University School of Medicine
Source:Eurekalert  

Related medicine news :

1. Peter Harker Joins Prometheus Research as Vice President of Sales
2. Research highlights role of protein pair in obesity regulation
3. UT researcher receives $2.4 million to research obesity, high-risk pregnancy
4. GUMCs Lombardi Hosts Symposium Exploring Future of Cancer Research and Personalized Medicine
5. MSU researcher linking breast cancer patients with alternative therapies
6. Researchers create drug to keep tumor growth switched off
7. Tiny fruit fly could offer big clues in fight against obesity, researcher says
8. Researchers Who Discovered First Genes for Stuttering will Present Findings to the National Stuttering Association
9. New Research Examines Impact of Health Care Reform on Regional Health Plans
10. Prevention Is Key Research Goal for Premature Babies, Scientists Say
11. Stuttering Foundation Hails New Research
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
IU research team discovers TB disease mechanism and molecule to block it
(Date:2/22/2017)... ... , ... Gevir, a New Zealand-based company that focuses on developing powder and ... to Amazon.com, the world’s largest online retailer. , The company was founded ... natural treatment for Shelley’s Multiple Sclerosis, which she’d been diagnosed with at 28 years ...
(Date:2/22/2017)... ... 2017 , ... South Bend’s Lunkerville, the award-winning TV series that catches real ... Water (HOW), a non-profit organization dedicated to helping military veterans relax, rehabilitate, and reintegrate ... traveling to Lake Denmark, New Jersey, to fish with war veteran Justin Vail from ...
(Date:2/22/2017)... Los Angeles, CA (PRWEB) , ... February 22, 2017 , ... ... with the recent addition of esteemed ophthalmologist, Dr. Steven H. Rauchman, practicing at ... are common in auto accidents, product liability, premise liability and other personal injury cases. ...
(Date:2/22/2017)... ... ... ANGLESTRONG , the new recovery management app with multiple innovative features ... and Google Play . Florida-based Sober Network, Inc., the premier provider of ... Angle to build ANGLESTRONG. The new recovery management app is a passion project for ...
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... ... communications company, launched a new media platform connecting healthcare technology professionals and other ... be followed by a quarterly publication starting on March 1, announced Michael J. ...
Breaking Medicine News(10 mins):
(Date:2/22/2017)... 22, 2017 Research and Markets has ... by Drug Molecule (Biologic, Small Molecule Drugs), By Route of ... Blockers) Outlook 2022" report to their offering. ... The global psoriasis ... 2016-2022 This report provides a detailed analysis of ...
(Date:2/22/2017)... 2017  Based on its recent analysis of ... recognizes SnooZeal, Inc. with the 2017 European New ... product that intelligently addresses the root causes of ... the clinically proven continuous transmucosal electrical stimulation therapy. ... one of the most accessible anti-snoring products available ...
(Date:2/22/2017)... Feb. 22, 2017  Applied Silver, the maker of SilvaClean®, ... the company,s advisory board. Ms. Barnes is the company,s third ... engineering, legal, and healthcare experts Scott McNealy , ... , J. Tress Ritter , and Leopold Selker ... brings more than three decades of nationally recognized clinical, nursing, ...
Breaking Medicine Technology: